» Articles » PMID: 15292068

Increased and Pathologic Emperipolesis of Neutrophils Within Megakaryocytes Associated with Marrow Fibrosis in GATA-1(low) Mice

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2004 Aug 5
PMID 15292068
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

Deletion of megakaryocytic-specific regulatory sequences of GATA-1 (Gata1(tm2Sho) or GATA-1(low) mutation) results in severe thrombocytopenia, because of defective thrombocytopoiesis, and myelofibrosis. As documented here, the GATA-1(low) mutation blocks megakaryocytic maturation between stage I and II, resulting in accumulation of defective megakaryocytes (MKs) in the tissues of GATA-1(low) mice. The block in maturation includes failure to properly organize alpha granules because von Willebrand factor is barely detectable in mutant MKs, and P-selectin, although normally expressed, is found frequently associated with the demarcation membrane system (DMS) instead of within granules. Conversely, both von Willebrand factor and P-selectin are barely detectable in GATA-1(low) platelets. Mutant MKs are surrounded by numerous myeloperoxidase-positive neutrophils, some of which appear in the process to establish contact with MKs by fusing their membrane with those of the DMS. As a result, 16% (in spleen) to 34% (in marrow) of GATA-1(low) MKs contain 1 to 3 neutrophils embedded in a vacuolated cytoplasm. The neutrophil-embedded GATA-1(low) MKs have morphologic features (high electron density and negativity to TUNEL staining) compatible with those of cells dying from para-apoptosis. We suggest that such an increased and pathologic neutrophil emperipolesis may represent one of the mechanisms leading to myelofibrosis by releasing fibrogenic MK cytokines and neutrophil proteases in the microenvironment.

Citing Articles

The Variation in the Traits Ameliorated by Inhibitors of JAK1/2, TGF-β, P-Selectin, and CXCR1/CXCR2 in the Model Suggests That Myelofibrosis Should Be Treated by These Drugs in Combination.

Gobbo F, Martelli F, Di Virgilio A, Demaria E, Sarli G, Migliaccio A Int J Mol Sci. 2024; 25(14).

PMID: 39062946 PMC: 11277099. DOI: 10.3390/ijms25147703.


CXCL8 and its cognate receptors CXCR1/CXCR2 in primary myelofibrosis.

Vermeersch G, Proost P, Struyf S, Gouwy M, Devos T Haematologica. 2024; 109(7):2060-2072.

PMID: 38426279 PMC: 11215396. DOI: 10.3324/haematol.2023.284921.


Recent advances in therapies for primary myelofibrosis.

Vainchenker W, Yahmi N, Havelange V, Marty C, Plo I, Constantinescu S Fac Rev. 2023; 12:23.

PMID: 37771602 PMC: 10523375. DOI: 10.12703/r/12-23.


Cell-in-Cell Structures in Gastrointestinal Tumors: Biological Relevance and Clinical Applications.

Druzhkova I, Ignatova N, Shirmanova M J Pers Med. 2023; 13(7).

PMID: 37511762 PMC: 10381133. DOI: 10.3390/jpm13071149.


Inhibition of CXCR1/2 reduces the emperipolesis between neutrophils and megakaryocytes in the Gata1 model of myelofibrosis.

Arciprete F, Verachi P, Martelli F, Valeri M, Balliu M, Guglielmelli P Exp Hematol. 2023; 121:30-37.

PMID: 36863479 PMC: 11780361. DOI: 10.1016/j.exphem.2023.02.003.